UBS Group
UNCY icon

UBS Group’s Unicycive Therapeutics UNCY Stock Holding History

UBS Group’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$325K Buy
69,377
+49,933
+257% +$368K ﹤0.01% 6494
2026
Q1 		$128K Sell
19,444
-461
-2% -$3.02K ﹤0.01% 6882
2025
Q4 		$115K Buy
19,905
+14,460
+266% +$77.2K ﹤0.01% 6841
2025
Q3 		$23.7K Buy
+5,445
New +$23.7K ﹤0.01% 8045
2025
Q2 		– Sell
-955
Closed -$5.49K – 10849
2025
Q1 		$5.49K Buy
+955
New +$5.82K ﹤0.01% 8987
2024
Q4 		– Hold
0
– – – 9864
2024
Q3 		– Hold
0
– – – 10088
2024
Q2 		– Sell
-439
Closed -$4.32K – 9440
2024
Q1 		$6.05K Buy
439
+421
+2,339% +$5.1K ﹤0.01% 7486
2023
Q4 		$153 Sell
18
-54
-75% -$353 ﹤0.01% 8862
2023
Q3 		$617 Sell
72
-45
-38% -$421 ﹤0.01% 8378
2023
Q2 		$1.5K Buy
+117
New +$1.83K ﹤0.01% 7906
2022
Q4 		– Sell
-119
Closed -$1K – 11160
2022
Q3 		$1K Sell
119
-330
-73% -$2.42K ﹤0.01% 10049
2022
Q2 		$4K Buy
+449
New +$4.29K ﹤0.01% 9141
2022
Q1 		– Sell
-527
Closed -$11K – 10931
2021
Q4 		$11K Buy
527
+465
+750% +$11.6K ﹤0.01% 8696
2021
Q3 		$2K Buy
+62
New +$1.78K ﹤0.01% 8998

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

UBS Group's UNCY Position: Q2 2026 in Review

UBS Group increased its Unicycive Therapeutics (UNCY) stake by 257% in Q2 2026, buying an estimated $368K and bringing the position to 69,377 shares worth $325K. The position accounts for ﹤0.01% of the portfolio, ranked #6494.

UBS Group first reported a position in UNCY in Q3 2021 and has held it in 13 quarters since. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • UBS Group held 69,377 shares of Unicycive Therapeutics worth $325K as of Q2 2026.
  • UBS Group bought 49,933 Unicycive Therapeutics shares in Q2 2026, an estimated $368K.
  • Unicycive Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6494 holding.
  • UBS Group first reported a position in Unicycive Therapeutics in Q3 2021 and has held it in 13 quarters since.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.